Kraig Biocraft Laboratories’ Prepares for First Monster Silk™ Textiles

LANSING, Mich., May 5, 2014– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig”), the leading developer of advanced spider silk based fibers, announced today that Warwick Mills, Inc. (“Warwick”), a leader in the engineering and development of advanced technical textiles and protective materials, is preparing to weave the first textiles with Kraig’s Monster Silk™ recombinant spider silk.  This is part of Kraig’s collaborative development initiative of advanced spider silk based textiles.

Kraig previously shipped Monster Silk™ yarn to Warwick, which after studying the material, requested that it be processed to additional specifications.  The material was shipped back to Kraig and then studied by a silk spinning expert who analyzed the fibers. The fibers were then processed according to the directions and specifications of the spinning expert.  Recently, Kraig received the reprocessed Monster Silk™ and shipped the material to Warwick.  Warwick is now testing and analyzing Kraig’s Monster Silk™ recombinant spider silk and determining the best ply and cord twisting for yarn optimization in preparation for creating sample textiles.

“We appreciate and respect the fact that Warwick asked us to reprocess the material instead of just moving forward at full speed with weaving or knitting,” said Kraig CEO and founder, Kim Thompson. “Warwick has taken the time to do this right.  As a result, the development of Monster Silk™ based textiles is at an exciting stage, Warwick is preparing to create the first Monster Silk™ textiles.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Launches New Investor Relations Website

Some Corporate Updates To Be Delivered, in Parallel, Via Social Media

LANSING, Mich., April 28, 2014— Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of advanced spider silk based fibers, today invites shareholders, and other followers of the Company’s developments, to visit the new Kraig investor relations website at www.kblbinvestors.com.  The Company is also announcing the launch of social media pages at Facebook and Twitter. The Company may add additional pages at other sites.

“Kraig has been a true trailblazer in applied biotechnology.  As we’ve concentrated on making discoveries in the laboratory, we’ve held off from establishing a social media presence and avoided prematurely incorporating many other public relations tools.  As the Company moves towards commercialization, we’ve achieved a stage in our growth where we can benefit from improved communications. We need to inform industry about what we’ve accomplished, both in the laboratory and in executing our recombinant spider silk commercialization plan,” said Company Founder and CEO, Kim K. Thompson.

“Kraig’s shareholders are one of the keys to our success and these tools should help us keep them informed.  Some of the website content will be designed specifically with our shareholders in mind.

“We view ourselves as the world leader in our exciting field of biotechnology innovation.  As such, we are sensitive to the competitive environment surrounding our inventions and laboratory discoveries.  We will remain guarded on certain details that could give aid to potential competitors, but, as we advance our business model, we plan on revealing additional information in upcoming Company press releases,” Thompson concluded.

The Company intends to distribute information on these sites in compliance with Securities and Exchange Commission’s Regulation Fair Disclosure.  For further Regulation FD information, please go to: http://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171513574#.UxdPrc7WBxA.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Is Testing Its Big Red™ Genetically Engineered Spider Silk

LANSING, Mich., April 22, 2014— Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, today announced that the Company received its fiber testing equipment, including customized components, to test its latest genetically engineered prototype fiber, Big Red™.

The Company announced that it created Big Red™, a new genetically engineered silk fiber, last fall, by using spider silk gene sequences.  Preliminary testing indicated that Big Red™ might have properties of strength and flexibility that could have potential commercial applications.

The Company ordered testing equipment to verify the preliminary results and, after taking delivery, had the equipment customized to account for the unique nature of recombinant spider silk based fibers.

“We are excited to perform a more rigorous evaluation of Big Red™ spider silk with the new equipment. We are hopeful of having definitive test results within the next several weeks.  So far, we are seeing a lot of variability, which may be an indication of genetic variation within the transgenic colony.  Not only will these tests provide us the first comprehensive set of data concerning Big Red™, and potently guide us in improving that transgenic, but it’s also the first major assessment of the new equipment,” said Company founder and CEO, Kim Thompson.

The Company intends to use the testing equipment to increase the laboratory’s research and development effectiveness by providing researchers with more rapid feedback on the results of their work.  The ability to quickly gather and analyze data is expected to greatly improve the effectiveness of the Company’s ongoing work in artificial selection of various strains of transgenic silkworms and potentially reduce the commercialization timeline for future fibers.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Welcome Susie to Kraig Biocraft Laboratories, Inc.

I am pleased to announce an important and much needed addition to our team.  Many of you may have noticed some subtle, and not so subtle, improvements in our communications, website management and general operation efficiency over the last few weeks.  That is due in great part to the addition of our new office administrator, Susie.

Susie’s experience is a terrific fit for KBLB.  She earned her bachelor’s degree in Communication from Wayne State University. Her previous work experience covers a broad spectrum of both big and small innovative companies.

As most of you know, Kraig has always operated with incredibly lean staffing in order to leverage the most research and development possible from our operating budget.  For all practical purposes, the addition of an office administrator has doubled the size of our corporate administrative team.

I am confident that the positive impacts we have seen in corporate communications and increased efficiency in many other areas will continue and accelerate over the coming months.

Kraig welcomes Susie on board for this exciting voyage.

Kim Thompson, CEO
Kraig Biocraft Laboratories, Inc.
www.KraigLabs.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (Ticker: KBLB), is a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

Monster Silk(TM) Production Surprises Company by Hitting New Milestone

LANSING, Mich., March 24, 2014 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that its genetically engineered spider silk, Monster Silk(TM), production program has more than doubled in productivity.

During the pilot production program, the yield rate of viable silk cocoons was approximately 30%. At those rates, the cost structure warranted the conversion of the pilot test program to a much larger scale.

The latest reports from the current production ramp up point to a dramatic and unexpected increase in yield to 70%; more than double the output efficiency shown during the pilot phase.

The initial assessment from the Company’s scientific team is that the Monster Silkworms(TM) are acclimating to the production environment.

“This dramatic boost in productivity was a surprise to us. Our plan was to methodically increase productivity rates over the next 18 months. Our team had drawn up plans that included selective breeding and cross breeding to achieve those goals. To see such a remarkable gain in so short a time was beyond our expectations. The obvious benefits, should these rates continue, would include reduced production costs and reduced ramp up time,” said Company Founder and CEO, Kim K. Thompson.

“With this doubling in efficiency, we need to focus on emplacing the necessary infrastructure to support the increased productivity. As far as challenges go, these are good problems to have. We have already taken action to beef up our production infrastructure to support these larger numbers. The improvement in performance is dramatic; but, with such significant advancements I am cautious until I see that results are consistent over the next few months,” Thompson concluded.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Contact:

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories’ Spider Silk is on Track for Large Scale Production

Scientific Evaluation Team encouraged by Monster Silk™ Ramp up Program

LANSING, Mich., March 20, 2014— Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, today announced that its scientific evaluation team performed an onsite assessment and evaluation, at the request of the Company, of its genetically engineered recombinant spider silk, Monster Silk™, production ramp up. This production ramp up follows closely on the heels of the Company’s successful pilot production program, which finished in late 2013. The scientific evaluation team reported that the ramp up program is on track for large scale production of Monster Silk™. The team’s report also included specific recommendations for accelerating commercial scale production and for completing the transition from pilot production to commercial scale production.

“The scientific evaluation team’s findings reinforce our belief that this important program is working and warrants that we commit additional resources to our scale up of Monster Silk™ production.  This evaluation encourages us that we are on the right track to achieve our goal of large scale production. More importantly, the team found areas where we can improve our production efficiency in order to reach that goal.  We have already started to put these plans in place to strengthen the Monster Silk™ production program,” said Company Founder and CEO, Kim K. Thompson.

The goal of this program is to produce Monster Silk™ in metric ton quantities.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Vietnamese Deputy Prime Minister, Vu Van Ninh, hosts Kim Thompson, CEO of Kraig Biocraft Laboratories (OTC: KBLB) to discuss possibility of establishing Monster Silk production in Vietnam

Company’s CEO Announces Positive Assessment of Commercial Production Potential for Monster Silk(TM) in Traditional Silk Producing Region

LANSING, MI-(Feb 6, 2014) – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today some of the Company’s findings from a very successful mission to assess the potential to establish commercial production of the Company’s high technology silk fibers in Vietnam. Kim K. Thompson, the Company CEO and Founder, conducted meetings with high ranking Vietnamese officials, including, most notably, Deputy Prime Minister Vu Van Ninh, which was featured on Vietnam Television (VTV) National News and can be viewed at the following link: http://www.youtube.com/watch?v=fvZUqd5veZY.

“The main purpose of the trip was to investigate and discuss the possibility of establishing commercial scale production of Monster Silk™ in Vietnam,” said Thompson. “We inspected silk production locations and infrastructure, potential vendor supply chains and sourcing operations, as well as the scope and depth of the country’s sericulture industry. The trip confirmed that Vietnam has the qualities and infrastructure needed to sustain large scale production of advanced silk fibers. We believe that our technology has the potential to revitalize the silk industry.”

After meeting with DPM Ninh, Thompson’s delegation was accompanied by Vietnamese diplomats on a working visit to Lam Dong province. In Lam Dong, Thompson met with high ranking officials of the provincial government to discuss potential commercial production. 

“Our discussions were very detailed and ranged from technology, land use and building occupation, to employment considerations and import/export duties. I’m very encouraged by what we have seen and by the openness and forward thinking of our Vietnamese hosts. I believe that the Vietnamese see the tremendous potential for growth and mutual benefit. Excellent progress was made on every key issue. We are now conducting a deeper evaluation of the data, and look forward to the real possibility of launching commercial scale production of high technology fibers in South East Asia,” Thompson concluded.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

•  Vietnam Television

 Contact: Ben Hansel  Hansel Capital, LLC.  (720) 288-8495 ir@KraigLabs.com

Kraig is in Advanced Discussions Regarding the Establishment of Advanced Fiber Production in Vietnam

DALAT, Vietnam-(Jan. 9, 2014)- Kraig Biocraft Laboratories, Inc. (KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that the Company has been meeting with high level Vietnamese government officials, regarding the establishment of advanced fiber production in Vietnam. Reports of these meetings have been receiving wide coverage in Vietnamese press and television.

An example of the Vietnamese coverage can be found at the following link:

http://vovworld.vn/en-US/News/Kraig-Biocraft-Laboratories-CEO-welcomed-in-Hanoi/207937.vov

“Vietnam is a nation with a wealth of infrastructure and experience in raw silk fiber production,” said Company CEO and Founder, Kim K. Thompson. “We believe there is a natural fit between our desire to achieve large scale commercial production and Vietnam’s desire to modernize its industry and increase productivity,” continued Thompson.

“We are very excited about the possibility of working with Vietnam. Our discussions regarding commercial production have been very productive. We have been very well received and our hosts have been very gracious. I would like to thank the parties who have taken the time to help make this trip as fruitful as possible. I am very impressed with what I’ve seen in Vietnam, including their passion for sericulture,” Thompson concluded.

The Company’s CEO will continue a thorough evaluation and assessment process in Vietnam, before returning to the United States.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Contact: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com

Joint Intellectual Property Agreement Covers the Collaborative Development of Spider Silk Based Textiles

LANSING, Mich., Oct 21, 2013– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, and Warwick Mills, Inc. (“Warwick”), a leader in the engineering and development of advanced technical textiles and other protective materials, jointly announced today that they have signed a collaborative development agreement concerning the development and commercialization of advanced textiles utilizing Kraig’s Monster Silk(TM) recombinant spider silk technology.

Under terms of the agreement, the two companies will jointly develop innovative textile products based on Kraig’s Monster Silk(TM) fibers.  Under the terms of the agreement, the two companies will jointly own textile product related intellectual property which is developed as a result of the collaboration.  

Joint development will initially focus on Monster Silk(TM) weaving, testing and near term applications.  The companies believe that this collaborative relationship will help expedite the commercialization of Monster Silk(TM) and future spider silk based technical fibers.

“This collaborative undertaking represents a huge step forward in our commercialization efforts.  The pairing of Kraig’s spider silk technology with Warwick’s world-class technical textiles applications engineering and weaving abilities is a bold move which we believe will enhance and accelerate the penetration of spider silk into technical textile markets,” said Kraig CEO and founder, Kim Thompson.

“Warwick Mills is recognized for engineering technical textiles with protective applications and its ability to bridge the gaps between innovative technologies and market integration.  Their global reputation is built on the foundation of innovation and performance.  I believe the joint development agreement is an important milestone and that Warwick’s impressive capabilities makes them an ideal bridge builder between Kraig’s expertise in spider silk technologies and the capturing of market share in the technical textiles arena,” concluded Thompson.

“Warwick is looking forward to developing new textiles in cooperation with Kraig Biocraft Laboratories, and its Monster Silk(TM) technology.  Spider silk fibers are a powerful new technological approach to potentially opening up new application and markets,” stated Charles Howland, President of Warwick.

“The future of textiles will continue to be driven by innovation and we believe that our textile engineering capabilities and Kraig’s fibers can change the game in some important applications.  These technologies could potentially result in higher performance textiles which would enable very advanced safety and military equipment.  This collaborative agreement is a big step forward in the development of exciting new textiles with potential applications for the technical textiles and protective textiles marketplace,” concluded Howland.

About Warwick Mills

For the past century, Warwick Mills has been a leader in the engineering of technical textiles for protective applications. Warwick develops and integrates complex fiber composites for the most challenging safety applications. Its cooperative development strategy relies on its core technologies in technical textiles, custom adhesives, and performance coatings, from research and development to testing and full-scale manufacturing. This strategy ensures customer confidence for every challenge.

http://www.warwickmills.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com

The Company Plans on Producing Metric Tons of Recombinant Spider Silk in 2014

LANSING, Mich., Oct 07, 2013 (GLOBE NEWSWIRE via COMTEX) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of advanced spider silk based fibers, today announced the launching of the Company’s commercial production program with the recent hatching of its first batch of Monster Silk(TM) silkworms for commercial production.

Furthermore, the Company is currently expending resources to augment the scale of its Monster Silkworm(TM) production over the next 30 to 90 days. This move coincides with the Company’s planned strategy to rapidly increase its production capacity. The Company’s strategy is to commit the vast majority of its initial production capacity to a propagation program designed to increase its production population. A smaller portion of the first commercial production generation should also yield fibers which can be dedicated to the production of woven textile samples.

“Our launch of our commercial scale production of Monster Silk(TM) is a long awaited major milestone for Kraig, as we demonstrate our ability to convert recombinant spider silk, and Monster Silk(TM) most specifically, from an exciting laboratory technology to a marketable product,” said, CEO and founder, Kim K. Thompson. “We believe that rolling out the world’s first recombinant spider silk commercial production project will only expand our global development prospects, for Monster Silk(TM) and other high technology fibers.”

“It has taken many years to go from my initial concept of recombinant spider silk to the laboratory production of Monster Silk(TM) and now the actual launch and scaling up of the commercial scale production. I want to thank our investors and, most particularly, the research scientists, whose work and dedication has made this long anticipated day possible.”

“Given the current planned production schedule, we could theoretically be producing Monster Silk(TM) in metric ton quantities by early January. A more conservative estimate, given the realities of launching such a ground breaking and commercially unique project, would be to reach that major milestone in mid 2014. This move reaffirms our view that Kraig is the world’s leading developer of recombinant spider silk technologies,” concluded Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com